18F-AZD4694 PET 显像判定淀粉样蛋白β阳性阈值的研究
该研究纳入176名受试者(年轻成人、认知正常老年人和认知障碍者),比较五种方法确定18F-AZD4694 PET淀粉样蛋白β阳性的定量阈值。ROC曲线、高斯混合模型和脑脊液Aβ42/Aβ40比值比较得到的阈值收敛于1.51至1.56 SUVR之间,其中1.55 SUVR具有可靠的判别准确性。
要点
- 五种方法中四种收敛于1.51–1.56 SUVR,支持1.55 SUVR作为阳性阈值。
- 基于年轻对照均值±2SD的1.33 SUVR阈值与其他方法不一致,会将多数老年人判为阳性。
- 定量阈值可用于仲裁视觉判读分歧或边界病例。
核心结论
- 18F-AZD4694 PET阳性阈值1.55 SUVR在多种方法间获得良好收敛,具有可靠判别准确性。
研究设计与样本
- 研究评估176人,包括年轻成人22名、认知正常老年人89名和认知障碍者65名,均接受18F-AZD4694 PET、腰椎穿刺、结构MRI和APOEε4基因分型。
主要发现
- 基于视觉分类的ROC曲线最佳切点为1.55 SUVR。
- 基于临床分类的ROC曲线最佳切点为1.56 SUVR。
- 高斯混合模型最佳切点为1.55 SUVR。
- 与脑脊液Aβ42/Aβ40比值比较的最佳切点为1.51 SUVR。
- 年轻对照均值±2SD得到的阈值为1.33 SUVR,与其他方法不一致,且将多数老年人标记为Aβ阳性。
关键数值与推荐
- 18F-AZD4694 PET阳性定量阈值为1.55 SUVR,基于视觉分类、临床分类和高斯混合模型等多种方法收敛。
临床怎么用
- 临床淀粉样蛋白PET目前主要依赖视觉判读,定量阈值1.55 SUVR可帮助仲裁判读者之间的分歧或用于边界病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Amyloid-β deposition into plaques is a pathologic hallmark of Alzheimer disease appearing years before the onset of symptoms. Although cerebral amyloid-β deposition occurs on a continuum, dichotomization into positive and negative groups has advantages for diagnosis, clinical management, and population enrichment for clinical trials. 18F-AZD4694 (also known as 18F-NAV4694) is an amyloid-β imaging ligand with high affinity for amyloid-β plaques. Despite being used in multiple academic centers, no studies have assessed a quantitative cutoff for amyloid-β positivity using 18F-AZD4694 PET. Methods: We assessed 176 individuals [young adults (n = 22), cognitively unimpaired elderly (n = 89), and cognitively impaired (n = 65)] who underwent amyloid-β PET with 18F-AZD4694, lumbar puncture, structural MRI, and genotyping for APOEε418F-AZD4694 values were normalized using the cerebellar gray matter as a reference region. We compared 5 methods for deriving a quantitative threshold for 18F-AZD4694 PET positivity: comparison with young-control SUV ratios (SUVRs), receiver-operating-characteristic (ROC) curves based on clinical classification of cognitively unimpaired elderly versus Alzheimer disease dementia, ROC curves based on visual Aβ-positive/Aβ-negative classification, gaussian mixture modeling, and comparison with cerebrospinal fluid measures of amyloid-β, specifically the Aβ42/Aβ40 ratio. Results: We observed good convergence among the 4 methods: ROC curves based on visual classification (optimal cut point, 1.55 SUVR), ROC curves based on clinical classification (optimal cut point, 1.56 SUVR) gaussian mixture modeling (optimal cut point, 1.55 SUVR), and comparison with cerebrospinal fluid measures of amyloid-β (optimal cut point, 1.51 SUVR). Means and 2 SDs from young controls resulted in a lower threshold (1.33 SUVR) that did not agree with the other methods and labeled most elderly individuals as Aβ-positive. Conclusion: Good convergence was obtained among several methods for determining an optimal cutoff for 18F-AZD4694 PET positivity. Despite conceptual and analytic idiosyncrasies linked with dichotomization of continuous variables, an 18F-AZD4694 threshold of 1.55 SUVR had reliable discriminative accuracy. Although clinical use of amyloid PET is currently by visual inspection of scans, quantitative thresholds may be helpful to arbitrate disagreement among raters or in borderline cases.
引用
- Therriault J, Benedet AL, Pascoal TA, et al. Determining Amyloid-β Positivity Using 18F-AZD4694 PET Imaging. J Nucl Med. 2020. PMID: 32737243. doi:10.2967/jnumed.120.245209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。